KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Inventory (2020 - 2025)

Moderna (MRNA) has disclosed Inventory for 6 consecutive years, with $153.0 million as the latest value for Q4 2025.

  • Quarterly Inventory rose 30.77% to $153.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $153.0 million through Dec 2025, up 30.77% year-over-year, with the annual reading at $153.0 million for FY2025, 30.77% up from the prior year.
  • Inventory for Q4 2025 was $153.0 million at Moderna, down from $332.0 million in the prior quarter.
  • The five-year high for Inventory was $2.1 billion in Q3 2022, with the low at $117.0 million in Q4 2024.
  • Average Inventory over 5 years is $732.2 million, with a median of $490.5 million recorded in 2021.
  • The sharpest move saw Inventory soared 2965.96% in 2021, then crashed 78.71% in 2023.
  • Over 5 years, Inventory stood at $1.4 billion in 2021, then tumbled by 34.14% to $949.0 million in 2022, then tumbled by 78.71% to $202.0 million in 2023, then crashed by 42.08% to $117.0 million in 2024, then skyrocketed by 30.77% to $153.0 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $153.0 million, $332.0 million, and $240.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.